Systematic review and meta analysis

Musculoskeletal ultrasound for treating rheumatoid arthritis to target—a systematic literature review

Ettore Silvagni1,*, Sara Zandonella Callegher2,*, Eleonora Mauric3, Sofia Chiricolo3, Nikolaus Schreiber4, Annarita Tullio5, Alen Zabotti6, Carlo Alberto Scirè7,8, Christian Dejaco2,4 and Garifallia Sakellariou9

Abstract

Objective. We aimed to systematically review the literature to retrieve evidence on the diagnostic and prognostic value of musculoskeletal ultrasound for a treat to target (T2T) approach in RA.

Methods. Eight research questions were developed addressing the role of ultrasound (including different ultrasound scores and elementary lesions) for diagnosis, monitoring and prognosis of RA. PubMed and EMBASE were searched (2005–2020). Articles on RA and reporting data on musculoskeletal ultrasound were included and extracted according to the underlying questions, and risk of bias assessed according to the study design.

Results. Out of 4632 records, 60 articles were included. Due to clinical heterogeneity, meta-analysis was not possible. Ultrasound better predicted disease relapses with respect to clinical examination in patients in remission, while both methods performed similarly in predicting response to therapy, achievement of remission and radiographic progression. Ultrasound was superior to clinical examination in diagnosing joint involvement using another imaging modality, such as magnetic resonance imaging, as reference. Limited ultrasound scores performed like more extensive evaluations for the detection of joint inflammation and for outcome prediction. Higher ultrasound scores of synovitis were linked to poor outcomes at all disease stages, but a specific cut-off distinguishing between low- and high-risk groups did not emerge.

Conclusions. These data confirm the pivotal role of ultrasound when evaluating synovial inflammation and when identifying RA patients at higher risk of relapse. Further research is needed to better define the role of ultrasound in a T2T management strategy in moderately-to-highly active RA.

Key words: RA, imaging, ultrasound, diagnosis, prognosis, prediction, systematic literature review

Rheumatology key messages

- Musculoskeletal ultrasound confirmed its value in diagnosing synovitis and predicting relapse.
- Reduced ultrasound scores perform comparably to the extensive ones.
- Knowledge on the impact of ultrasound applied to RA management is still scarce.
Introduction

In recent years, the management of RA has undergone major progress, given the availability of new drugs, early diagnosis, prompt treatment initiation, and treat-to-target (T2T) strategy [1–4]. Specifically, treating disease to target is recommended by EULAR and other international guidelines, since its adoption leads to improved clinical, functional and imaging outcomes [2, 5]. One crucial aspect of T2T is to regularly measure disease activity using clinical composite scores. These scores, however, may lead to over- or underestimation of joint inflammation, given that non-inflammatory pain (e.g. painful comorbidities) may result in high scores whereas subclinical synovitis is not sufficiently captured [6–9].

Musculoskeletal ultrasound is more sensitive and specific than clinical examination in detecting synovial inflammation; nonetheless, its role in the follow-up of RA patients is controversial [10]. Ultrasound is increasingly used in clinical practice for diagnosis and follow-up of these patients [11]; however, clinical trials adopting a T2T strategy by incorporating imaging as a parameter in early RA patients failed their primary endpoints [12–14]. The main objective of these trials was to test whether a strategy aiming at clinical plus imaging remission was superior to a conventional strategy targeting clinical remission alone. While there was a trend towards better radiographic outcomes in the clinical plus imaging groups, the primary clinical endpoints, e.g. achievement of clinical remission, were not met. The value of imaging as part of T2T in patients with elevated clinical scores, in which imaging might help to distinguish between true joint inflammation and non-inflammatory causes of increased scores, has not been investigated yet.

The present systematic literature review (SLR) was conducted in preparation of a clinical trial promoted by the Italian Society of Rheumatology (SIR). The aim of this trial will be to investigate the value of ultrasound as part of a T2T strategy in RA patients with doubtful clinical inflammation as compared with clinical evaluation alone, trying to exploit the possibility of correctly identifying inflammatory vs non-inflammatory conditions by ultrasound. Herein, we summarize the evidence regarding the value of ultrasound compared with other imaging to detect active inflammation and ultrasound vs clinical assessment to predict different outcomes in RA. We also investigate the performance of different ultrasound composite scores, ultrasound elementary lesions and grades of lesions for monitoring and outcome prediction of RA patients.

Methods

The SLR was conducted following the PRISMA 2020 Checklist (Supplementary Table S1, available at Rheumatology online) [15]. The areas of interest covered the value of ultrasound, including different scores and lesions, in the diagnosis of active inflammation compared with different imaging modalities, different ultrasound scores and different ultrasound lesions, as well as in the prediction of clinical, radiographic and functional outcomes compared with clinical assessment. Eight research questions were developed and transformed into PICOIs (Patients, Intervention, Comparator, Outcome, Study type) (Table 1; Supplementary Table S2, available at Rheumatology online), sharing pre-defined inclusion and exclusion criteria.

Search strategies were applied to PubMed and EMBASE (1 January 2005–21 June 2020) (Supplementary Table S3, available at Rheumatology online). Searches were performed by one author (G.S.) and limited to humans, adults and English language. The timespan was chosen to assess comparable equipment. Records were imported into bibliographic management software (Zotero) and duplicates removed. Five investigators (S.C., E.M., E.S., N.S., S.Z.C.) performed screening, selection, data extraction and bias assessment, working in five pairs comprising different combinations of reviewers to assess titles and abstracts. Pairs of reviewers assessed the eligibility of the full-texts. Only studies including at least 10 patients with RA were included. RA populations of interest included: early RA, longstanding RA, RA patients on conventional synthetic/biologic/targeted synthetic DMARDs, RA patients in clinical remission or with active disease. All study designs (including letters reporting original data) were eligible except case reports, editorials and narrative reviews. Disagreement between reviewers was resolved by consensus within the pairs. Another investigator (G.S.) was involved as a tie-breaker if consensus could not be obtained. Data from included articles were extracted in pre-specified forms, including general information on the article, features of the population and, when available, 2 × 2 tables of diagnostic accuracy, odds ratios (OR) and risk ratios with 95% CI. For diagnostic studies, the outcomes of interest were the diagnosis of inflammatory lesions and of active disease, while for predictive studies, the outcomes were clinical response, clinical relapse, joint damage on imaging, disability and maintenance of treatment. Risk of bias (RoB) of included studies was assessed with the Newcastle–Ottawa scale for cohort and case–control studies [16], the Cochrane RoB (RoB2) for randomized-controlled trials (RCTs), and the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for diagnostic studies [17]. Results are presented in evidence tables. Meta-analysis was not performed due to clinical heterogeneity.

Results

Of 4632 articles evaluated, 60 studies were finally included (Fig. 1; Supplementary Figs S1 and S2, available at Rheumatology online). There were four RCTs, 40 prospective cohorts, 15 cross-sectional studies and one retrospective observational study. Studies referring to research questions about composite scores and grades of ultrasound lesions, as well as the diagnostic role of ultrasound for RA vs OA are summarized in the Supplementary Material, available at Rheumatology online. The risk of bias assessment is presented in Fig. 2 and in Supplementary Table S4, available at Rheumatology online.
Value of ultrasound compared with clinical examination to predict future outcomes

Studies are summarized in Fig. 3 and Supplementary Table S5, available at Rheumatology online. The risk of bias of included studies is summarized in Fig. 2.

**Clinical remission**

Three prospective studies [18–20], and one RCT [21], including 598 patients, compared ultrasound with clinical examination for the prediction of clinical remission. In the RCT (ARCTIC), DMARD-naïve early RA patients were followed up for 2 years by tight control aiming for clinical remission (DAS in 44 joints with ESR < 1.6). In half of the patients, clinical plus ultrasound remission [no joints with power Doppler (PD) signal] was targeted. Failure to achieve sustained DAS remission at 16–24 months was predicted in both univariate and multivariate analysis only by a higher tender joint count (TJC) [OR (95% CI) 0.90 (0.86, 0.94), \( P < 0.001 \)] but not by ultrasound parameters [21]. Horton et al. reported that in early RA neither ultrasound nor DAS28-CRP predicted remission [19], while in the other two studies in patients with long-lasting RA both clinical examination and ultrasound predicted remission to a similar extent [18, 20]. Of note, the TaSER study was not included in the present SLR, as it did not fulfill the inclusion criteria. In fact, it enrolled a mixed population of RA and undifferentiated arthritis, and separate results for RA patients were not available [14].

In summary, in the ARTIC, only TJC predicted remission at 16–24 months, while in prospective studies there were no differences between clinical examination and ultrasound in this regard.

**Response to therapy**

Four prospective studies including 345 patients explored the predictive value of ultrasound vs clinical parameters for treatment response [22–25], while in two studies, ultrasound was not of additional value over clinical parameters.
## Risk of bias assessment

### In patients with RA, what is the value of ultrasound versus clinical examination to predict outcome? (observational studies) *Newcastle-Ottawa Scale*

| Study              | Selection | Comparability | Outcome/Exposure |
|--------------------|-----------|---------------|------------------|
| Brown, 2008 [30]   |           |               |                  |
| Chen, 2017 [36]    |           |               |                  |
| De Miguel, 2017 [37]|           |               |                  |
| Di Carlo, 2019 [18]|           |               |                  |
| Dougdados, 2013 [38]|          |               |                  |
| Ellegaard, 2011 [25]|         |               |                  |
| Filipou, 2018 [8]  |           |               |                  |
| Fisher, 2016 [23]  |           |               |                  |
| Foltz, 2012 [26]   |           |               |                  |
| Geng, 2016 [27]    |           |               |                  |
| Harman, 2018 [39]  |           |               |                  |
| Harman, 2015 [40]  |           |               |                  |
| Horton, 2016 [19]  |           |               |                  |
| Ikeda, 2013 [41]   |           |               |                  |
| Inanc, 2016 [50]   |           |               |                  |
| Iwamoto, 2015 [31] |           |               |                  |
| Kawashiri, 2017 [32]|          |               |                  |
| Matsuo, 2020 [28]  |           |               |                  |
| Naredo, 2017 [42]  |           |               |                  |
| Naredo, 2015 [29]  |           |               |                  |
| Saleem, 2012 [30]  |           |               |                  |
| Sapundzhieva, 2018 [20]|       |               |                  |
| Sciré, 2009 [33]   |           |               |                  |
| Ten Cate, 2018 [22]|          |               |                  |

### In patients with RA, what is the value of ultrasound versus clinical examination to predict outcome? (RCTs) **Cochrane RoB (RoB2) tool for RCTs**

| Study                             | Performance | Detection | Attrition | Reporting | Other |
|-----------------------------------|-------------|-----------|-----------|-----------|-------|
| Lamers-Karnebek, 2017 [34]        |             |           |           |           |       |
| Paulshus Sundlisæter, 2018 [21]   |             |           |           |           |       |
| Paulshus Sundlisæter, 2018 [43]   |             |           |           |           |       |

### In patients with RA, what is the diagnostic value of ultrasound for active inflammation as compared to clinical examination, using other imaging as reference standard? ***QUADAS 2***

| Study              | Selection | Test | Standard | Flow/Timing |
|--------------------|-----------|------|----------|-------------|
| Abdelazifer, 2019 [44]|         |      |          |             |
| Damjanov, 2012 [45]  |           |      |          |             |
| El-Kelegy, 2017 [46]|           |      |          |             |
| Ogishima, 2014 [47]  |           |      |          |             |
| Tamguichi, 2014 [48] |           |      |          |             |
| Zou, 2020 [49]       |           |      |          |             |

### In patients with RA, what is the value of ultrasound lesion A versus ultrasound lesion B to predict outcome? *Newcastle-Ottawa Scale*

| Study              | Selection | Comparability | Outcome/Exposure |
|--------------------|-----------|---------------|------------------|
| Chen, 2017 [36]    |           |               |                  |
| Filipou, 2018 [8]  |           |               |                  |
| Funck-Brentano, 2013 [54]|       |               |                  |
| Geng, 2016 [27]    |           |               |                  |
| Harman, 2018 [39]  |           |               |                  |
| Harman, 2015 [40]  |           |               |                  |
| Horton, 2016 [19]  |           |               |                  |
| Ikeda, 2013 [41]   |           |               |                  |
| Inanc, 2016 [50]   |           |               |                  |
| Janta, 2016 [52]   |           |               |                  |
| Kawashiri, 2017 [32]|          |               |                  |
| Nozaki, 2018 [51]  |           |               |                  |
| Ramires, 2017 [55] |           |               |                  |
| Saleem, 2012 [30]  |           |               |                  |
| Saleem, 2010 [53]  |           |               |                  |
| Sciré, 2009 [33]   |           |               |                  |
| Ten Cate, 2018 [22]|          |               |                  |

The risk of bias was defined through different tools, depending on study design. For the Newcastle–Ottawa scale: for selection red corresponds to ≤1 star, yellow to 2–3 stars, green to 4 stars; for comparability, red corresponds to 0 stars, yellow to 1, green to 2; for exposure/outcome red corresponds to ≤1 star, yellow to 2 stars, green to 3 stars. For the QUADAS 2: for selection, red corresponds to 3 no, yellow to 1 yes or at least 1 unclear, green to 3 yes; for test: red corresponds to 2 no, yellow to 1 yes or at least 1 uncertain, green to 2 yes; for standard, red corresponds to 2 no, yellow to 1 yes or at least 1 unclear, green to 2 yes; for flow/timing: red corresponds to 3 no, yellow to 1–2 yes or at least 1 unclear, green to 3 yes. For RCTs: red corresponds to low risk of bias, yellow to some concerns on the risk of bias, red to high risk of bias. *Risk of bias assessed through the Newcastle-Ottawa scale; **Risk of bias assessed through the Cochrane tool for RCTs; ***Risk of bias assessed through the QUADAS. RCT: randomized controlled trial. Colour version available online.
Fig. 3 Summary of studies evaluating ultrasound vs clinical examination to predict outcomes

The main finding of the studies (ultrasound being inferior, equal or superior to clinical examination for predicting outcomes) is represented by the grey box. Studies on remission and response were performed in patients with active disease, while those on relapse in patients in clinical remission. Radiographic progression was assessed both in studies on clinical remission and active disease. US: ultrasound.
Examination alone [22, 23], Ellegaard et al. found that PD, quantified by the colour fraction in the wrist, was the only predictor of maintenance of an anti-TNFα after 1 year in patients with long-lasting RA and moderate-high disease activity [25]. Conversely, Inanc et al. reported that a higher baseline 28-joints PD score was the only parameter which, in multivariate analysis, predicted a lack of EULAR response to TNFα blockers at 3 months [OR (95% CI) 0.86 (0.75–0.98)] in patients with long-lasting, biologic-naïve RA and high baseline disease activity [24].

Globally, ultrasound and clinical examination had a similar value in predicting response to therapy in active RA.

Clinical relapse

Ten studies, including 1240 subjects, compared the values of ultrasound and clinical examination for predicting clinical relapse of patients in remission at 6 or 12 months. Eight of these concluded that ultrasound outperformed clinical examination in both longstanding [26–32] and early RA [33]. In five articles, PD positivity was the best predictor of relapse in multivariate analysis among several clinical and ultrasound parameters, yielding ORs between 3.08 and 13.9 [26–29, 33]. In the study by Iwamoto et al., both PD and grey scale (GS) synovitis (GSS) outperformed clinical parameters [31], while according to Saleem et al. both PD and disability (Health Assessment Questionnaire) were independently associated with increased risk of flare [31]. In the study by Kawashiri et al. the presence of ultrasound-detected bone erosions predicted relapse within 12 months after treatment discontinuation [OR (95% CI) 8.35 (1.78, 53.2)] [32]. In contrast to these results, in a secondary analysis of the STARTER study (the only analysis of the study eligible for inclusion in this research question), the addition of ultrasound to clinical variables did not improve the prediction of future flares in patients with baseline DAS28 < 3.2 [8]. An RCT (POET-US) in longstanding RA with low disease activity revealed that ultrasound had limited value to predict a flare after the discontinuation of anti-TNFα when added to clinical parameters [34]. In summary, 8 out of 10 studies demonstrated that PD-positive synovitis outperformed clinical examination in predicting flares at 6 or 12 months in longstanding and early RA patients in clinical remission.

Radiographic progression

Eight prospective studies [35–42] and one RCT [43], enrolling 880 patients, compared ultrasound and clinical examination for predicting radiographic progression. In two studies, a low PD score in early RA predicted the absence of radiographic progression at 12 months better than the swollen joint count (SJC) and the TJC [39, 42]. In the study by de Miguel et al. the absence of PD but not clinical indexes predicted the lack of radiographic progression at 12 months in longstanding RA [37]. Chen et al. reported that delayed improvement of GSS one month after starting an anti-TNFα more accurately predicted 1-year radiological damage than clinical measures such as DAS28 [36]. In four studies, X-ray progression at 6, 12 and 24 months was similarly predicted by ultrasound and clinical parameters [35, 38, 40, 41]. In the sub-analysis of the ARTIC RCT, ACR/EULAR Boolean remission, absence of PD signal and minimal GSS (sum score ≤ 2 of 0–96 joints) performed similarly for the prediction of no radiographic progression from 12–24 months after baseline [ACR/EULAR Boolean remission: OR (95% CI) 3.2 (1.3, 8.4); absence of PD signal: OR (95% CI) 3.6 (1.3, 10.0); minimal GSS: OR (95% CI) 3.2 (1.2, 8.0)] in a cohort of moderately active early RA patients [43]. However, in the main analysis of the ARTIC study, there was a borderline statistically significant difference at 24 months concerning the change of radiographic joint damage, favouring the ultrasound-guided group.

In summary, absence of ultrasound-detected inflammation seems to have a slight superiority over absence of clinically detected inflammation regarding radiographic progression at 12–24 months.

Value of ultrasound compared with clinical examination to detect active inflammation, using other imaging as reference standard

Six studies, including 286 patients, addressed this issue [44–49] (Table 2; Supplementary Table S6, available at *Rheumatology* online), four with a cross-sectional [44, 46, 48, 49] and two with a prospective design. The risk of bias of the included studies is reported in Fig. 2 [45, 47]. In all the studies, ultrasound was superior to clinical examination in detecting inflammatory lesions, using MRI as the reference. In three studies, ultrasound performed better than clinical examination of swollen joints at wrists and MCP joints to identify active inflammation in longstanding RA, in terms of area under the receiver operating characteristic curve (AUC) (AUC for sonographic identification of synovitis/effusion 0.65–0.75 vs clinical examination 0.56–0.65, sensitivity (ultrasound 0.27–0.64 vs clinical examination 0.31–0.52), specificity (ultrasound 0.95–1 vs clinical examination 0–0.98), positive predictive value (ultrasound 0.65–1 vs clinical examination 0.45–0.66) and negative predictive value (ultrasound 0.41–0.88 vs clinical examination 0.78–0.86) [45, 47, 48]. In the remaining three studies, ultrasound was superior to clinical examination in detecting inflammatory lesions in shoulders, temporomandibular and MTP joints [44, 46, 49].

In summary, ultrasound was superior to clinical examination in detecting inflammatory lesions in different joints, with MRI used as reference.

Value of different elementary ultrasound lesions to predict future outcomes

Seventeen studies evaluated the role of specific ultrasound lesions for outcome prediction (Fig. 4; Supplementary Table S11, available at *Rheumatology* online).
Table 2: Studies on the diagnostic value for active inflammation compared with clinical examination

| Study            | Population                  | Study design       | Site             | Reference standard | Results                                                                 |
|------------------|-----------------------------|--------------------|------------------|--------------------|-------------------------------------------------------------------------|
| Abdelzaher, 2019 [44] | RA with shoulder pain       | Cross-sectional    | Shoulders        | MRI                | LHB tenosynovitis  
Se 0.87  
Sp 0.98  
SAD bursitis  
Se 0.72  
Sp 0.95  
Subscapularis tenosynovitis  
Se 0.92  
Sp 0.98 |
| Damjanov, 2012 [45]     | Longstanding RA with active disease | Prospective cohort | MCPs, wrists     | MRI                | US synovitis/effusion AUC (95% CI)  
Wrists 0.75 (0.43, 1)  
MCP 0.65 (0.53, 0.76) | Clinical synovitis/effusion AUC (95% CI)  
Wrist 0.36 (0.04, 0.68)  
MCP 0.55 (0.43, 0.66) |
| El-Melegy, 2017 [46]    | Longstanding RA             | Cross-sectional    | TMJ joint        | MRI                | US abnormalities were less frequent than MRI abnormalities (77.5% vs 82.5%), in particular regarding erosions. US assessment was positive in 77.5% of cases, while clinical examination in 67.5% |
| Ogishima, 2014 [47]     | Longstanding RA             | Prospective cohort | MCP, PIP, wrists | MRI                | Ultrasound  
Wrist  
Se (95% CI) 0.52 (0.37, 0.66)  
Sp (95% CI) 0 (0, 0.26)  
MCP  
Se (95% CI) 0.31 (0.21, 0.41)  
Sp (95% CI) 0.98 (0.95, 0.99) | Clinical examination  
Wrist  
Se (95% CI) 0.43 (0.37, 0.49)  
Sp (95% CI) 0.3 (0.24, 0.44)  
MCP  
Se (95% CI) 0.69 (0.48, 0.85)  
Sp (95% CI) 0.58 (0.49, 0.67) |
| Taniguchi, 2014 [48]    | Longstanding RA             | Cross-sectional    | MCPs, wrists     | MRI                | Ultrasound  
GS  
Se (95% CI) 0.59 (0.47, 0.70)  
Sp (95% CI) 0.35 (0.24, 0.46)  
PD  
Se (95% CI) 0.69 (0.48, 0.85)  
Sp (95% CI) 0.58 (0.49, 0.67) |
| Zou, 2020 [49]          | Early RA                    | Cross-sectional    | MTPs 2–5         | MRI                | Ultrasound  
GS  
Se (95% CI) 0.59 (0.47, 0.70)  
Sp (95% CI) 0.35 (0.24, 0.46)  
PD  
Se (95% CI) 0.69 (0.48, 0.85)  
Sp (95% CI) 0.58 (0.49, 0.67) |

AUC: area under the receiver operating characteristic curve; GS: grey scale; PD: power Doppler; Se: sensitivity; Sp: specificity; TMJ: temporo-mandibular joint.
Global risk of bias of the included studies is reported in Fig. 2.

Clinical response
Among the five studies, including 475 patients, assessing clinical response, two [19, 22] did not find any association between GSS and PD synovitis and different definitions of clinical remission at 12 months in early RA. In the work by Harman et al. [40] instead, time-integrated values for GSS, PD-positive synovitis, GS tenosynovitis and PD-positive tenosynovitis were linked to DAS44 at 1 year. Among patients starting an anti-TNFα, Inanc et al. [24] highlighted that clinical responders at 3 months had higher PD score at baseline; this was not observed for GSS. Nozaki et al. did not confirm these results in a 54-week study, suggesting that a synovial hypertrophy index, defined as the sum of the synovial hypertrophy scores for each joint, predicted clinical response, while PD did not [50].

Overall, it appears that GSS and PD synovitis might be more useful in predicting clinical remission in long-standing RA, while their role in early RA is still questionable.

Clinical relapse
Studies were selected when a comparison among different elementary lesions was available, independently from clinical evaluation; therefore, the main conclusions differ slightly from the previous research question. Seven studies enrolling 736 patients assessing clinical relapse were included. Data concerning the association of GS and PD scores with the risk of flare are heterogeneous, with some studies reporting that simultaneous PD-positive tenosynovitis and PD-synovitis predicted flare in long-standing RA [adjusted OR (95% CI) 2.09 (1.06, 4.13)] [8],

The main finding of the studies (power Doppler being inferior, equal or superior to grey scale for predicting outcomes) is represented by the grey box. Studies on disease activity included patients with active disease, while those on relapse were performed in clinical remission. Radiographic progression was assessed both in studies on clinical remission and in studies on active disease. GS: grey scale; PD: power Doppler.
while others reported that PD-positive synovitis better predicted flare than GSS [30, 33, 51], even though statistical significance was not always reached [27, 52]. Other researchers reported no value of GSS or PD synovitis for predicting flares [32]. One possible source of bias is that, in some studies, it is unclear if ultrasound influenced treatment decisions or not [30, 52].

Globally, the risk of relapse in RA patients in remission was higher for PD-positive synovitis than for GS-synovitis, despite some exceptions.

Radiographic progression
Seven studies, including 726 patients, evaluated radiographic progression at 6–18 months. In one prospective study of patients starting anti-TNFα [36], baseline GSS and PD did not predict radiographic progression at 1 year, while the modification of GSS score at 1 month did, with patients yielding no improvement in GSS experiencing higher structural damage than those improving. Similarly, the cumulative accrual of PD scores at 12 and 24 weeks compared with baseline was associated with radiographic progression at 24 weeks in RA patients starting methotrexate [41]. In another study on early RA [40], GSS and PD synovitis at baseline, but not GS and PD tenosynovitis, predicted radiographic progression at 1 year [53]. Similarly, baseline GSS, PD-synovitis and ultrasound-detected erosions predicted radiographic progression at 1 year [39], but none of these lesions performed better than another. In two studies on patients in remission, radiographic progression did not correlate with baseline GS and PD scores, while structural deterioration occurred more frequently in patients who fulfilled a more stringent definition of ultrasound synovitis (including simultaneous synovial hyperplasia ≥2 and PD or concurrent presence of GS tenosynovitis and synovitis) than in those not fulfilling it [8, 54]. In summary, data on the comparison of different ultrasound lesions to predict radiographic progression in RA is heterogeneous. While in early RA, baseline GSS and PD-synovitis predicted radiographic progression, this could not be confirmed for long-standing RA.

The results of the research questions ‘Value of restricted ultrasound scores to detect inflammation, using extensive ultrasound assessment as reference standard’, ‘Value of different ultrasound scores to detect inflammation, using clinical examination as reference standard’, ‘Value of different ultrasound scores to predict future outcomes’, ‘Value of different elementary ultrasound lesions for diagnosis of active RA vs osteoarthritis’ and ‘Value of grade of different elementary ultrasound lesions to predict future outcomes’ are depicted in the Supplementary File and Supplementary Tables S7–S14, available at Rheumatology online.

Discussion
The exact role of musculoskeletal ultrasound in guiding treatment decisions in RA has not been fully clarified yet [11, 55, 56]. The objectives of this SLR were to evaluate studies comparing ultrasound and clinical examination to predict outcomes of interest for RA patients, as well as its value to detect active inflammation. Globally, ultrasound, in particular PD, is helpful to identify active disease, and enables the prediction of clinical outcomes, mainly in patients in clinical remission. Data remain heterogeneous in the context of moderate-to-high disease activity, and hence further research is necessary in this patients’ group.

Sixty studies were retrieved, mostly observational, pertinent to all research questions. Since the main aim was to assess the value of ultrasound vs clinical examination to predict specific outcomes, we analysed its role in general and, more specifically, the role of specific scores, elementary lesions and grades. Relating to the first research question of our SLR (i.e. the value of ultrasound vs clinical examination to predict outcomes of interest), PD-positive synovitis might be more helpful than clinical examination in predicting flares in clinical remission. In fact, 8 out of 10 studies demonstrated that ultrasound performed better than clinical scores, especially PD-positive synovitis, suggesting that sonography can help clinicians to decide about how to manage patients in remission. EULAR recommendations for the use of imaging in RA [10], developed almost 10 years ago, suggested a role of ultrasound in monitoring disease activity, without clarifying how much, to which joints, and to which population sonography should be applied. Our study helps to select the population (i.e. RA patients in clinical remission) in which ultrasound is of highest value. ARCTIC and TaSER trials, which included ultrasound in the treatment strategy [12–14], failed their primary endpoints, and DMARDs should probably not be increased or started de novo in early RA patients who have already reached clinical remission. Concerning the most relevant question, whether treatment should be de-escalated once clinical remission has been achieved, ultrasound can provide important insights. Patients without clinical activity but PD synovitis, for example, are at a higher risk of flare and radiographic progression, and it would probably not be wise to step down treatment in this group; rather, these patients should undergo close clinical (and maybe also imaging-based) monitoring.

Globally, ultrasound and clinical evaluation had a similar value in predicting clinical response in active RA, and no information can be inferred regarding a possible role for sonography in personalized treatment. Since the only RCT [21] was performed in patients with early DMARD-naïve RA, no RCT specifically addressed our main research question on whether RA patients with active disease despite effective treatment could benefit of a US-guided approach to clarify the main treatment strategy to select. We also want to highlight the limitations of the ARCTIC and TaSER trials (the latter was not included in this SLR because it did not meet the inclusion criteria), like the absence of blinding of the ultrasound findings chosen for decisions-making or the included population. These limitations prevent the generalization to all RA patients of the conclusions of these studies [57]. Moreover, an RCT on ultrasound in a T2T strategy
should bridge the discrepancy between clinical perception of the disease status and index-based evaluation of disease activity. We also lack specific information on distinct disease-populations (e.g. oligo-articular or mono-articular involvement in RA) in which ultrasonography might be applied for a T2T strategy. With respect to structural outcomes, our SLR retrieved some evidence suggesting a slight superiority of ultrasound over clinical evaluation for the prediction of radiographic progression. In particular, absence of ultrasound inflammation was associated with lower radiographic damage. Our results confirm the suggestion to use ultrasound by EULAR [10], but should be replicated in RCTs.

In line with EULAR recommendations [10, 58, 59], we confirmed that ultrasound was superior to clinical examination in detecting active inflammation using MRI as reference. Ultrasound revealed a higher sensitivity detecting subclinical inflammation in a considerable proportion of patients, and also a higher specificity by excluding inflammation in patients with tenderness but no swelling. This provides the basis to study the value of ultrasound in moderately active RA in order to inform treatment decisions and potentially to prevent overtreatment of patients.

Another question refers to the minimum joint count that should be scanned by sonography. In our SLR (see Supplementary Results, available at Rheumatology online) ultrasound scores ranged from 3 to 44 joints, but none of this was validated for clinical practice. Most studies were performed in longstanding RA, leaving areas of uncertainty in early phases of the disease and in remission. Globally, simplified scores gave similar information to extensive ones in terms of synovitis detection, while erosive damage was tendentially underestimated by the former. Restricted scores outperformed clinical examination in the detection of synovial inflammation to a similar extent as extensive scores, indicating that these limited ultrasound scores could be a valid, less time consuming alternative for clinical practice.

We then assessed the role of specific lesions in predicting clinical outcomes. The risk of flare in remission tended to be higher in patients with PD-positive synovitis than in those with GS-synovitis only. Since some sonographic tools like the GLOESS [60] contemplate high cumulative scores even in the absence of PD, the separate evaluation of PD may be considered when such scores are used for studies and/or clinical practice. The role of specific ultrasound lesions in predicting response and/or radiographic progression in active RA is uncertain and should be evaluated further. In early RA patients, baseline GS, PD and erosions predicted subsequent radiographic progression, but none of these lesions attained superiority over the others [39, 53].

With respect to the diagnostic question concerning elementary lesions, we found that high-grade GSS, PD-positive synovitis, erosions and tenosynovitis were all helpful in discriminating RA from other diseases, particularly OA, acknowledging that the number and quality of studies were low. Finally, the majority of studies assessing the grade of ultrasound lesions highlighted that higher grade of PD-synovitis performed better than lower scores in predicting outcomes of interest (clinical response, radiographic progression) [10].

Our study has some limitations, which partly relate to those of the primary studies. First, most research was performed using ultrasound in ‘non-realistic’ settings, mainly by interpreting sonographic findings independently from clinical evaluation. While this might be required for blinding, in clinical routine, ultrasound is mostly used as an extension of clinical examination, particularly in doubtful situations. The risk of bias of the included studies was generally moderate, in particular concerning exposure and comparability, and this affected the overall quality of the SLR itself. Third, there was a broad clinical heterogeneity among the studies. This could be explained by the attempt of investigators to clarify a specific research question rather than replicating another study.

In conclusion, ultrasound assessment, and in particular PD-positive synovitis, outperformed clinical examination concerning the prediction of relapse and radiographic progression in the setting of clinical remission. Moreover, since sonography outperformed clinical examination in detecting active disease, more research is needed to clarify the value of ultrasound in predicting clinical response to therapy or selection of adequate treatment, as well as to elucidate the role of sonography in a T2T strategy. This could be of value specifically in cases of moderately active disease, a clinical context in which composite indexes confirm several gaps [1, 9]. Here, sonography might serve as a tiebreaker in avoiding overtreatment.

Acknowledgements

All the authors have made substantial contributions to the conception or design of the work, or acquisition, analysis, interpretation of data; have drafted the work or revised it critically for important intellectual content; finally approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Disclosure statement: E.S. received research support from AbbVie and consulting/speaker’s fees from AbbVie, Novartis and Pfizer. C.D. has received consulting/speaker’s fees from AbbVie, Eli Lilly, Janissen, Novartis, Pfizer, Roche, Galapagos and Sanofi. G.S. received consulting/speaker’s fees from AbbVie, BMS and Galapagos. The other authors declare no conflicts of interest.

Data availability statement

The authors have full control of all primary data and agree to allow the journal to review data if requested.
Supplementary data

Supplementary data are available at Rheumatology online.

References

1 Smolen JS, Landewe RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685–99.

2 Smolen JS, Breedveld FC, Burmester GR et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3–15.

3 Silvagni E, Giollo A, Sakellariou G et al. One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2020;38:181–94.

4 Silvagni E, Sakellariou G, Bortoluzzi A et al. One year in review 2021: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2021;39:705–20.

5 Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis: ACR RA treatment recommendations. Arthritis Care Res 2016;68:1–25.

6 Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

7 Bellis E, Scirè CA, Carrara G et al. Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. Rheumatol 2016;55:1826–36.

8 Filippou G, Sakellariou G, Scirè CA et al. The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study. Ann Rheum Dis 2018; 77:1283–9.

9 McKenna F. Treatment of moderate rheumatoid arthritis. Rheumatology 2020;61:478–9.

10 Colebatch AN, Edwards CJ, Østergaard M et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013;72:804–14.

11 Di Matteo A, Mankia K, Azukizawa M, Wakefield RJ. The role of musculoskeletal ultrasound in rheumatoid arthritis continuum. Curr Rheumatol Rep 2020;22:41.

12 Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg B et al. Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis. JAMA 2019;321:461–72.

13 Haavardsholm EA, Aga A-B, Olsen IC et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 2016;354:i4205.

14 Dale J, Stirling A, Zhang R et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis 2016;75:1043–50.

15 Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.

16 Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (30 September 2020, date last accessed).

17 Whiting PF, Rutjes AWS, Westwood ME et al.; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.

18 Di Carlo M, Salaffi F, Gremese E et al.; GISEA Study Group. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. Eur J Intern Med 2019;66:57–61.

19 Horton SC, Tan AL, Freeston JE et al. Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. Rheumatology 2016;55:1177–87.

20 Sapundzhieva T, Karaillova R, Batalov A. Musculoskeletal ultrasound for predicting remission in patients with rheumatoid arthritis: results from a 1-year prospective study. Rheumatol Int 2018;38:1891–9.

21 Paulshus Sundlisæter N, Olsen IC, Aga A-B et al.; ARCTIC study group. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology 2018;57:2022–31.

22 Ten Cate DF, Jacobs JWG, Swen WAA et al. Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients? Arthritis Res Ther 2018;20:15.

23 Fisher BA, Donatien P, Filer A et al. Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. Clin Exp Rheumatol 2016;34:1072–6.

24 Inanc N, Ozen G, Direskeneli H. Predictive value of ultrasonographic assessment of disease activity in response to tumor necrosis factor-α inhibitor treatment in rheumatoid arthritis: a prospective cohort study. Clin Exp Rheumatol 2016;34:156.

25 Ellegaard K, Christensen R, Torp-Pedersen S et al. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study. Rheumatology 2011;50:506–12.

26 Foltz V, Gandjbakhch F, Etchepare F et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease...
progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 2012;64:67–76.

27 Geng Y, Han J, Deng X, Zhang Z. Deep clinical remission: an optimised target in the management of rheumatoid arthritis? Experience from an ultrasonography study. Clin Exp Rheumatol 2016;34:581–6.

28 Matsuo H, Imamura A, Shimizu M et al. Prediction of recurrence and remission using superb microvascular imaging in rheumatoid arthritis. J Med Ultrasound 2020;47:131–8.

29 Naredo E, Valor L, De la Torre I et al. Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology 2015;54:1408–14.

30 Saleem B, Brown AK, Quinn M et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 2012;71:1316–21.

31 Iwamoto T, Ikeda K, Hosokawa J et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res 2014;66:1576–81.

32 Kawashiri SY, Fujikawa K, Nishino A et al. Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled. Arthritis Res Ther 2017;19:108.

33 Sciré CA, Montecucco C, Codullo V et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 2009; 48:1092–7.

34 Lamers-Kamebeek FB, Luime JJ, Ten Cate DF et al. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors. Rheumatology 2017;56:1560–5.

35 Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;59:2958–67.

36 Chen Y-C, Su F-M, Hsu S-W et al. Predictor of hand radiological progression in patients with rheumatoid arthritis receiving TNF antagonist therapy by change in grayscale synovitis-a preliminary study. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 2017;23:73–6.

37 de Miguel E, Pecondón-Espairol A, Castaño-Sánchez M et al.; The ECO-DAI Group. A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. Rheumatol Int 2017;37:1347–56.

38 Dougados M, Devauchelle-Pensec V, Ferlet JF et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2013;72:665–71.

39 Harman H, Tekeoglu I. Clinical and ultrasonographic findings in patients with early rheumatoid arthritis: an 18-month follow-up cohort study. Med J Bakirkoy 2018;14:155–64.

40 Harman H, Tekeoglu I, Takçi S et al. Improvement of large-joint ultrasonographic synovitis is delayed in patients with newly diagnosed rheumatoid arthritis: results of a 12-month clinical and ultrasonographic follow-up study of a local cohort. Clin Rheumatol 2015;34:1367–74.

41 Ikeda K, Nakagomi D, Sanayama Y et al. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents. J Rheumatol 2013;40:1967–76.

42 Naredo E, Collado P, Cruz A et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 2007;57:116–24.

43 Paulshus Sundlisæter N, Aga A-B, Olsen IC et al.; ARCTIC study group. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. Ann Rheum Dis 2018;77:1421–5.

44 Abdelzaher MG, Tharwat S, AbdElkhaled A, Abdelsalam A. Ultrasound versus magnetic resonance imaging in the evaluation of shoulder joint pathologies in a cohort of rheumatoid arthritis patients. Int J Rheum Dis 2019;22:2158–64.

45 Damjanov N, Radunovic G, Prodanovic S et al. Construct validity and reliability of ultrasound disease activity score in assessing joint inflammation in RA: comparison with DAS-28. Rheumatology 2012;51:120–8.

46 El-Melegy DN, El-Khouly RM, Mwafi MEE-D, Zyton HAE-H. Magnetic resonance imaging versus musculoskeletal ultrasound in the evaluation of temporomandibular joint in rheumatoid arthritis patients. Egypt Rheumatol 2017; 39:207–11.

47 Ogishima H, Tsuboi H, Umeda N et al. Analysis of subclinical synovitis detected by ultrasonography and low-field magnetic resonance imaging in patients with rheumatoid arthritis. Mod Rheumatol 2014;24:60–8.

48 Taniguchi D, Tokunaga D, Oda R et al. Maximum intensity projection with magnetic resonance imaging for evaluating synovitis of the hand in rheumatoid arthritis: comparison with clinical and ultrasound findings. Clin Rheumatol 2014;33:911–7.

49 Zou H, Beattie KA, Allen M, Ioannidis G, Larch MJ. Ultrasonography supplements clinical exam to improve early rheumatoid arthritis disease activity monitoring in metatarsophalangeal joints. Clin Rheumatol 2020;39:1483–91.

50 Nozaki Y, Ri J, Sakai K et al. Prediction of therapeutic responses with ultrasonography in RA patients treated with an anti-TNF drug: a retrospective cohort study. Immunol Med 2018;41:129–35.

51 Janta I, Valor L, De la Torre I et al. Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy;
which joints and tendons should be assessed to predict unstable remission? Rheumatol Int 2016;36:387–96.

52 Saleem B, Keen H, Goeb V et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636–42.

53 Funck-Brentano T, Gandjbakhch F, Etchepare F et al. Prediction of radiographic damage in early arthritis by sonographic erosions and power Doppler signal: a longitudinal observational study. Arthritis Care Res 2013;65:896–902.

54 Ramirez J, Cuervo A, Celis R et al. Biomarkers of clinical relapse and radiological progression in patients with rheumatoid arthritis in remission. Observational study of 5 years of follow-up. Ann Rheum Dis 2019;78:1120.

55 Ranganath VK, Hammer HB, McQueen FM. Contemporary imaging of rheumatoid arthritis: clinical role of ultrasound and MRI. Best Pract Res Clin Rheumatol 2020;34:101593.

56 Carstensen SMD, Terslev L, Jensen MP, Østergaard M. Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis. Curr Opin Rheumatol 2020;32:264–72.

57 D’Agostino MA, Boers M, Wakefield RJ, Emery P, Conaghan PG. Is it time to revisit the role of ultrasound in rheumatoid arthritis management? Ann Rheum Dis 2017;76:7–8.

58 Nagy G, Roodenrijs NM, Welsing PM et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2022;81:20–33.

59 Nagy G, Roodenrijs NM, Welsing PM et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2021;80:31–5.

60 D’Agostino M-A, Wakefield RJ, Berner-Hammer H et al.; OMERACT-EULAR-Ultrasound Task Force. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Ann Rheum Dis 2016;75:1763–9.